ADVERTISEMENT
References
- Lim SH, Kim SY, Kim K, et al. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget. 2017;8(2):3237‐3245. doi:10.18632/oncotarget.13700
- Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650‐665.
- Cheng J, Qu L, Wang J, et al. High expression of FLT3 is a risk factor in leukemia. Mol Med Rep. 2018;17(2):2885‐2892.
- Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299‐312.
- The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6.
- Moreira RB, Peixoto RD, de Sousa Cruz MR. Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification. Case Rep Oncol. 2015;8(1):83‐87.
- Ger M, Kaupinis A, Petrulionis M, et al. Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer. Anticancer Res. 2018;38(10):5759‐5765.
- Borowczyk M, Szczepanek-Parulska E, Dębicki S, et al. High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage. Ther Adv Med Oncol. 2020;12:1758835920907534.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement